title: Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials.
abstract: Seborrheic dermatitis is a common, chronic, relapsing inflammatory skin disorder that manifests as erythema, scaling and pruritus in sebum gland-rich areas of the skin. The objective of this article is to evaluate the clinical efficacy of pimecrolimus 1% cream in the treatment of seborrheic dermatitis compared with corticosteroids, antimycotics, placebo or no intervention. Pimecrolimus 1% cream appears to be a well-tolerated and effective treatment for seborrheic dermatitis. It has comparable efficacy, in terms of decreasing severity of erythema, scaling and pruritus, to the standard treatments: topical corticosteroids and antimycotics. However, future studies with more standardized measures of treatment outcome are recommended. More studies may also be conducted to further evaluate pimecrolimus 1% cream as a long-term maintenance therapy for seborrheic dermatitis.
authors.affiliation: Section of Dermatology, Department of Internal Medicine, University of the Philippines-Philippine General Hospital, Taft Avenue, Manila 1000, Philippines.
authors.forename: Charlene U
authors.initials: CU
authors.lastname: Ang-Tiu
authors.forename: Chandra F
authors.initials: CF
authors.lastname: Meghrajani
authors.forename: Clarita C
authors.initials: CC
authors.lastname: Maano
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D065095:Calcineurin Inhibitors; D002626:Chemistry, Pharmaceutical; D012628:Dermatitis, Seborrheic / Q000188:drug therapy* / Q000473:pathology; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000737:chemistry; D006801:Humans; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D016559:Tacrolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry; D016896:Treatment Outcome
chemical_list: D065095:Calcineurin Inhibitors; D003879:Dermatologic Agents; C117268:pimecrolimus; D016559:Tacrolimus